BC Week In Review | Jul 7, 2017
Clinical News

India set to approve Biocad's biosimilar rituximab

Biocad CJSC (Saint Petersburg, Russia) said India’s Central Drugs Standard Control Organization (CDSCO) recommended approval of AcellBia (BCD-020), a biosimilar of rituximab. Biocad expects the product be approved next month, with a launch planned for...
BC Week In Review | May 26, 2014
Company News

Biocad, Pharmstandard, Millhouse LLC deal

Pharmstandard and Russian investment firm Millhouse are acquiring a combined 70% stake in Russian biosimilar play Biocad. Pharmstandard will acquire a 20% stake, while Millhouse will acquire a 50% stake. Biocad founder and CEO Dmitri...
BC Extra | May 24, 2014
Company News

Pharmstandard, Millhouse to gain stake in Russian biosimilar play

Pharmstandard OJSC (RTS:PHST; LSE:PHST) and Russian investment firm Millhouse LLC are acquiring a combined 70% stake in Russian biosimilar company Biocad CJSC (St. Petersburg, Russia). Pharmstandard will acquire a 20% stake, while Millhouse will acquire...
BC Week In Review | Apr 28, 2014
Clinical News

AcellBia rituximab regulatory update

Biocad said the Russian Ministry of Health approved the company's AcellBia, a biosimilar of rituximab for autoimmune and cancer indications. Biocad said AcellBia is the first mAb biosimilar to be approved in Russia. The company...
BC Extra | Apr 23, 2014
Company News

Biocad's rituximab biosimilar approved in Russia

Biocad (St. Petersburg, Russia) said the Russian Ministry of Health approved the company's AcellBia (BCD-20), a biosimilar of autoimmune and cancer drug rituximab. Biocad said AcellBia is the first mAb biosimilar to be approved in...
Items per page:
1 - 5 of 5